Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
Ursula Fearon, PhD (she/her/hers)
Trinity College Dublin
Dublin, Dublin, Ireland
Disclosure(s): No financial relationships with ineligible companies to disclose
Christopher Ritchlin, MD, MPH
University of Rochester Medical Center
Canandaigua, NY, United States
Disclosure(s): No relevant disclosure to display
Jose Scher, MD
New York University School of Medicine
New York, NY, United States
Disclosure(s): AbbVie: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing)
The pathophysiology driving psoriatic arthritis (PsA) is unique compared to other forms of inflammatory arthritis, but identification of mechanisms which are unique and play a clear role in driving joint disease has proven challenging. This session seeks to highlight recent work which describes key processes, including perturbations in immune and stromal cells and the microbiome.
Speaker: Ursula Fearon, PhD (she/her/hers) – Trinity College Dublin
Speaker: Jose Scher, MD – New York University School of Medicine
Speaker: Christopher Ritchlin, MD, MPH – University of Rochester Medical Center